Efficacy and Safety of Crizotinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with ROS1 Rearrangement or MET Alteration: A Systematic Review and Meta-Analysis

ConclusionOur study highlighted and confirmed the efficacy of crizotinib in patients with NSCLC withROS1 orMET genetic alterations. Crizotinib had remarkable effects on advanced NSCLC withROS1 fusion, as previously reported. However, the role of this targeted therapy inMET-altered NSCLC remains investigational.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research